Ken Griffin Natera, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$97.75 - $129.67 $1.92 Million - $2.54 Million	-19,600 Reduced 32.29%	41,100 $5.22 Million
Q2 2024 Aug 14, 2024	BUY	$85.28 - $112.6 $409,344 - $540,480	4,800 Added 8.59%	60,700 $6.57 Million
Q1 2024 May 15, 2024	SELL	$59.21 - $92.9 $1.57 Million - $2.47 Million	-26,600 Reduced 32.24%	55,900 $5.11 Million
Q4 2023 Feb 14, 2024	BUY	$37.55 - $62.64 $2.09 Million - $3.49 Million	55,700 Added 207.84%	82,500 $5.17 Million
Q3 2023 Nov 14, 2023	BUY	$43.4 - $62.52 $577,220 - $831,516	13,300 Added 98.52%	26,800 $1.19 Million
Q2 2023 Aug 14, 2023	SELL	$47.08 - $55.16 $1.42 Million - $1.66 Million	-30,100 Reduced 69.04%	13,500 $656,000
Q1 2023 May 15, 2023	BUY	$36.57 - $58.29 $117,024 - $186,528	3,200 Added 7.92%	43,600 $2.42 Million
Q4 2022 Feb 14, 2023	SELL	$34.17 - $47.91 $621,894 - $871,961	-18,200 Reduced 31.06%	40,400 $1.62 Million
Q3 2022 Nov 14, 2022	BUY	$36.93 - $56.68 $18,465 - $28,340	500 Added 0.86%	58,600 $2.57 Million

528

119M

308K

191K

Ticker NTRA
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 96,957,400
Market Cap $16.3B
Description
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify sing...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.